Biotechnology
Nucleome Therapeutics, a leading biotechnology company spun out from Oxford University, will occupy a significant portion of the newly built Inventa building in Oxford's West End. This state-of-the-art complex is the first commercial science scheme delivered in the city's West End, strategically located within walking distance
Biotechnology industries
Eagle Genomics, a leading data science genomics company, has fallen into administration, marking the beginning of a sale process after struggling to adapt its business model. Founded in 2008 by Abel Ureta-Vital and Will Spooner, the company developed e[datascientist], a platform leveraging network science, AI, and hypergraph technologies to
United States. Securities and Exchange Commission
Seattle Genetics Inc. has recently filed a U.S. Securities and Exchange Commission (SEC) form SC 13D, disclosing beneficial ownership of certain registered equity securities. This filing, posted on May 8, 2015, provides essential information about the company's equity holdings. As a biotechnology company specializing in biological products,
United States. Securities and Exchange Commission
Avalanche Biotechnologies, a biotechnology company with a focus on biological products, filed a Form 4 document with the U.S. Securities and Exchange Commission (SEC) on May 7, 2015. The filing provided insights into the company's equity securities and the relationship between its directors, officers, and major shareholders.
Pharmaceutical industry
Illumina, a leading manufacturer of DNA sequencing equipment, and Merck Serono, the biopharmaceuticals business of Merck KGaA, have formed a collaboration to develop a universal next-generation sequencing-based oncology diagnostic. The partnership aims to create a comprehensive tool for precision medicine in cancer treatment, with the goal of enabling clinical trials
Pharmaceutical industry
The US stock market closed slightly lower on Monday, with the S&P 500 down by nearly 20 points and the Dow Jones closing 11 points down at 18,116. This decline was largely driven by losses in financials, health care, and transportation stocks, which wiped out the gains
United States. Securities and Exchange Commission
United Therapeutics Corp. recently posted a U.S. Securities and Exchange Commission (SEC) filing for Form 8-K on December 17, 2014. The filing, which can be accessed through the SEC's website, reveals important information about the company's corporate changes and material events. As a biotechnology company
United States. Securities and Exchange Commission
La Jolla Pharmaceutical Co, a US-based pharmaceutical company, has submitted a statement of ownership regarding its security on Form 4 to the Securities and Exchange Commission (SEC). This filing, dated December 12, 2014, is a requirement for every director, officer, or owner of more than ten percent of a class
Pharmaceutical industry
Pharmaceutical stocks declined on Friday, January 3, 2014, as investors grew concerned about the industry's momentum. The Dow Jones Industrial Average (^DJI) rose 14 points (0.1%) to 16,456, while the NYSE advances/declines ratio sat at 1,718 issues advancing vs. 1,181 declining with 172
Pharmaceutical industry
US stocks closed at record highs on Tuesday, with the Dow Jones Industrial Average and S&P 500 posting their best annual gains since 1995 and 1997, respectively. Ahead of the New Year's Day holiday, consumer confidence and home prices also showed positive signs, beating expectations. The
Pharmaceutical industry
Regeneron Pharmaceuticals, Inc. has settled its patent dispute with Genentech Inc., a unit of Swiss drug maker Roche Group, relating to U.S. ophthalmic sales of its injectable eye drug Eylea or aflibercept. The settlement grants Regeneron a non-exclusive license to certain patents relating to VEGF receptor proteins and other
Pharmaceutical industry
The biotech industry in 2011 achieved significant milestones with major drug approvals, deals, and advancements. However, the sector was also heavily affected by global economic worries and political fights over government debt in Europe and the United States. Despite this, life sciences companies raised a total of $82.4 billion
